Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis
Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection. A computerized literature search of PubMed, SCOPUS, EMBASE, EBSCO, Web of science, and Cochrane CENTRAL was conducted using relevant keywords. Data from eligible studies were pooled in a fixed effect meta-analysis model, using OpenMeta[Analyst] software.
Source: Journal of Infection and Public Health - Category: International Medicine & Public Health Authors: Hussien Ahmed, Abdelrahman Ibrahim Abushouk, Attia Attia, Mohamed Gadelkarim, Mohamed Gabr, Ahmed Negida, Mohamed M. Abdel-Daim Tags: Review Source Type: research
More News: Computers | Hepatitis | Hepatitis C | International Medicine & Public Health | Science | Study